Eligibility of all registered patients
Following our inclusion/exclusion criteria derived from Phase III trials of DOACs (Table 1), 4054 (51.8%) patients with NVAF were classified as the eligible group, whereas the remaining patients (n=3772, 48.2%) were classified as the ineligible group mainly because of CHADS2 score <2 (26.4%), renal dysfunction (9.5%), anaemia (6.4%), and chronic treatment with nonsteroidal anti-inflammatories (NSAIDs (4.0%) (Table 2 ).14